Biocryst Pharmaceuticals Stock Total Debt
| BCRX Stock | USD 7.15 0.18 2.46% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess BioCryst Pharmaceuticals' long-term financial health and intrinsic value.
Total Debt To Capitalization is likely to rise to 2.42 in 2025. BioCryst | Total Debt | Build AI portfolio with BioCryst Stock |
BioCryst Pharmaceuticals Company Total Debt Analysis
BioCryst Pharmaceuticals' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current BioCryst Pharmaceuticals Total Debt | 841.42 M |
Most of BioCryst Pharmaceuticals' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioCryst Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
BioCryst Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for BioCryst Pharmaceuticals is extremely important. It helps to project a fair market value of BioCryst Stock properly, considering its historical fundamentals such as Total Debt. Since BioCryst Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BioCryst Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BioCryst Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
BioCryst Short Long Term Debt Total
Short Long Term Debt Total |
|
Based on the latest financial disclosure, BioCryst Pharmaceuticals has a Total Debt of 841.42 M. This is 69.42% lower than that of the Biotechnology sector and 159.07% higher than that of the Health Care industry. The total debt for all United States stocks is 84.18% higher than that of the company.
BioCryst Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioCryst Pharmaceuticals' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioCryst Pharmaceuticals could also be used in its relative valuation, which is a method of valuing BioCryst Pharmaceuticals by comparing valuation metrics of similar companies.BioCryst Pharmaceuticals is currently under evaluation in total debt category among its peers.
BioCryst Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, BioCryst Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to BioCryst Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
BioCryst Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in BioCryst Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of BioCryst Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing BioCryst Pharmaceuticals' value.| Shares | Two Sigma Investments Llc | 2025-06-30 | 4.3 M | Arrowstreet Capital Limited Partnership | 2025-06-30 | 4.3 M | Two Sigma Advisers, Llc | 2025-06-30 | 4.2 M | Rp Management, Llc | 2025-03-31 | 3.8 M | Assenagon Asset Management Sa | 2025-06-30 | 3.6 M | Nuveen, Llc | 2025-06-30 | 3.5 M | Goldman Sachs Group Inc | 2025-06-30 | 3.5 M | Bank Of America Corp | 2025-06-30 | 2.8 M | Fisher Asset Management, Llc | 2025-06-30 | 2.8 M | Blackrock Inc | 2025-06-30 | 21.4 M | Vanguard Group Inc | 2025-06-30 | 20.5 M |
BioCryst Fundamentals
| Return On Equity | -19.25 | ||||
| Return On Asset | 0.0746 | ||||
| Profit Margin | (0.06) % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 1.98 B | ||||
| Shares Outstanding | 209.92 M | ||||
| Shares Owned By Insiders | 1.18 % | ||||
| Shares Owned By Institutions | 99.39 % | ||||
| Number Of Shares Shorted | 28.32 M | ||||
| Price To Earning | (7.11) X | ||||
| Price To Book | 56.59 X | ||||
| Price To Sales | 2.76 X | ||||
| Revenue | 450.71 M | ||||
| Gross Profit | 370.64 M | ||||
| EBITDA | 12.81 M | ||||
| Net Income | (88.88 M) | ||||
| Cash And Equivalents | 417.48 M | ||||
| Cash Per Share | 2.24 X | ||||
| Total Debt | 841.42 M | ||||
| Debt To Equity | 2.40 % | ||||
| Current Ratio | 5.19 X | ||||
| Book Value Per Share | (2.01) X | ||||
| Cash Flow From Operations | (52.02 M) | ||||
| Short Ratio | 12.15 X | ||||
| Earnings Per Share | (0.18) X | ||||
| Price To Earnings To Growth | (0.28) X | ||||
| Target Price | 16.36 | ||||
| Number Of Employees | 580 | ||||
| Beta | 1.05 | ||||
| Market Capitalization | 1.54 B | ||||
| Total Asset | 490.42 M | ||||
| Retained Earnings | (1.77 B) | ||||
| Working Capital | 261.58 M | ||||
| Current Asset | 65.99 M | ||||
| Current Liabilities | 64.45 M | ||||
| Net Asset | 490.42 M |
About BioCryst Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioCryst Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioCryst Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioCryst Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.